World Journal of
Pharmaceutical and Life Sciences

NEW FDA APPROVED DRUGS FOR THE TREATMENT FOR ATOPIC DERMATITIS

Saerah Simon*, Reza Rajesh, Roshni Acha Biju, Renuka R. and Elessy Abraham

ABSTRACT

Atopic Dermatitis (AD) is a highly pruritic chronic inflammatory skin disease that commonly presents during early childhood. It is a special form of eczematous dermatitis with wide range of severity. Several studies indicate that the disease is very common in western world with lifetime prevalence in children of 10% to 20%. In most patients it occurs before 5 yrs and typically clears by adolescence. AD has an immunologic basis. Both innate and adaptive immune responses are impaired in AD patients. Intense pruritis is a hallmark of the disease which leads to extensive scratching and further breakdown of the skin barrier. Treatment of atopic eczema should be based on a “stepped-care plan” where treatments are stepped up or down depending on the assessment of the state of the child’s skin by the physician. Both topical and systemic treatments are given for eczema. Topical corticosteroids and calcineurin inhibitors are used as topical anti-inflammatory agents. Patients should be carefully instructed about the use of topical glucocorticoids to avoid side effects. Newer drugs used in treatment of AD are Crisaborole ointment and Dupilumab injection. FDA approved these drugs on 14th December 2016 and 28th March 2017 respectively.

[Full Text Article]   [Download Certificate]